About the company:
A promising Biotech unicorn headquartered in a Tier-1 city in China. Dedicated to developing groundbreaking first-in-class innovative drugs, the company has successfully advanced its core assets into Phase II clinical trials with solid data readouts and strong financial backing.
about the team.
Led by a visionary founder and a scientific committee of industry veterans. You will be joining a highly dynamic and ambitious executive board, reporting directly to the CEO, and acting as the primary bridge between the company's scientific innovations and the global capital markets.

About the job:

• IPO Execution: Spearhead the company's upcoming HKEX Chapter 18A IPO process, leading the coordination with global sponsors, legal counsels, and auditors.
• Capital Strategy & IR: Formulate and execute comprehensive capital market strategies, actively pitch to top-tier institutional investors, and secure future financings.

• Strategic Finance & BD Support: Oversee group-level financial planning, build complex valuation models, and provide critical financial leadership for cross-border Business Development (License-in/out) and M&A activities.

   

Skills and experience required:

• Capital Market Track Record: Proven experience in successfully executing HKEX 18A IPOs, either as an in-house Biotech CFO or as a senior investment banker (VP/ED/MD level) from top-tier global or domestic securities firms.
• Technical Expertise: Exceptional financial modeling and valuation capabilities, with a deep understanding of biotech pipelines, clinical data, and BD transaction structuring.
• Investor Relations: Outstanding communication and presentation skills in both English and Mandarin, with established relationships with healthcare-focused long-only funds and institutional investors.

Please find more information here.